ÈýÒÚÌåÓý¹ÙÍø

Announcements

Dr. Collins welcomed everyone to this special meeting of ÈýÒÚÌåÓý¹ÙÍø IC Directors, which was called to provide additional information on the ÈýÒÚÌåÓý¹ÙÍø IRP-Pfizer Centers for Therapeutic Innovation.   

ÈýÒÚÌåÓý¹ÙÍø IRP-Pfizer Centers for Therapeutic Innovation: Chris Austin

Dr. Austin (NCATS) provided an overview of the proposed collaboration model, governance structure, and evaluation criteria for the joint project with the ÈýÒÚÌåÓý¹ÙÍø IRP and the Pfizer Centers for Therapeutic Innovation (CTI). He also summarized the statistics of the selected projects, the advantages to ÈýÒÚÌåÓý¹ÙÍø, and the potential logistical issues associated with this collaboration. The discussion focused on the dispute resolution process, the roll-out to the extramural community, status of trainees, potential expansion of the program, publication procedures, and policies for project approval.